According to the company, its latest laser recently received FDA clearance and CE mark approval.

According to the company, THR-149 is currently being evaluated in the KALAHARI Phase 2, Part B clinical trial as a potential treatment for patients who respond suboptimally to anti-VEGF, the standard of care for treatment of DME.

Medical, surgical management can be important tools.

While the 6-weekly regimen was less effective in improving the clinical activity score or exophthalmos than the higher dose regimen, it is an acceptable treatment choice for patients with marginal or lower clinical activity scores.

Neda Shamie, MD, explains how her practice has established procedures for incorporating light adjustable lenses into their cataract surgery workflow.

Neda Shamie, MD, reviews the case of a 56-year-old photographer who desires excellent midrange and distance vision with high contrast sensitivity.

Neda Shamie, MD, discusses the factors to consider when selecting cataract lenses for patients with monovision and emphasized how light adjustable lenses offer flexibility in correcting vision to the desired target after surgery.

Neda Shamie, MD, presents a case of a 65-year-old college professor with monovision who sought freedom from glasses following cataract surgery.

The project, a collaboration with researchers from the University of Maryland, holds promise for advancing new and more tolerable drug treatments for common chronic blinding eye diseases, including glaucoma and macular degeneration.

According to the company, AG-73305 was found to be safe and tolerable with no severe adverse effects after a single intravitreal injection of 0.5 mg and 1 mg in patients diagnosed with diabetic macular edema.

According to the company, topical administration is capable of delivering metformin to choroid, RPE, and retina.

SLT shows promise as treatment for millions of Africans with glaucoma.

Louis R. Pasquale, MD, FARVO, will be presented the award by previous winner Robert N. Weinreb, MD.

According to the company, the study has now reached its goal of 300 patients enrolled to evaluate ILUVIEN as a first line, baseline therapy for DME.

The investigative team wanted to provide physicians with reference guidelines to aid in the prevention and control of myopia.

Macular hole closure results from this novel treatment.